Follow-up human papillomavirus (HPV) testing 6 months after treatment is suggested for women with cervical intraepithelial neoplasm (CIN) 2/3.
However, the Pap smear remains the only feasible tool in areas with limited resources.
Our study aimed to evaluate the risk factors of recurrent CIN2/3 after excision treatment by follow-up Pap smear in a nationwide database.
